Liraglutide protects retinal cells from fat-induced damage through AMPK activation for potential AMD treatment | Research

The takeaway

Liraglutide protected ARPE-19 retinal pigment epithelium cells from free fatty acid-induced dysfunction through AMPK pathway activation and lipid homeostasis regulation, suggesting potential therapeutic application for age-related macular degeneration.

RPE protection via AMPK
Liraglutide activated AMPK to restore lipid homeostasis in retinal cells damaged by free fatty acids—addressing the core pathology of dry AMD

What the researchers found

Liraglutide: ↓FFA-induced RPE dysfunction. Mechanism: AMPK activation + lipid homeostasis regulation. Protected against: oxidative stress, lipid dysregulation, cellular dysfunction. AMD pathology-relevant model (ARPE-19 cells + FFA). Addresses drusen-related lipid accumulation.

Why it matters

AMD is the leading cause of irreversible blindness in the elderly with limited treatment for the dry (non-neovascular) form. Liraglutide addressing lipid-driven RPE damage could become the first treatment for dry AMD pathology.

How the study worked

In vitro ARPE-19 cells. FFA exposure model. Liraglutide treatment. AMPK pathway analysis. Lipid homeostasis markers. Oxidative stress assessment.

What this study cannot tell us

In vitro single cell type. ARPE-19 is an immortalized cell line. FFA model is simplified vs in vivo AMD. Clinical doses may differ. AMD involves multiple cell types and pathways.

How to read the evidence

In vitro mechanistic study. Good proof of concept for retinal GLP-1 protection.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs keep revealing new tissue-protective effects. Finding they protect retinal cells from the lipid damage that drives AMD connects metabolic health with eye health at the cellular level.

Questions still open

Could liraglutide eye drops treat dry AMD?
Does systemic semaglutide improve AMD biomarkers in diabetic patients?
Would AMPK-targeted drugs be more specific for retinal protection?

Common questions

Could GLP-1 drugs help with age-related blindness?

This laboratory study shows liraglutide protects the specialized cells at the back of the eye (retinal pigment epithelium) from the lipid damage that causes age-related macular degeneration. By activating the AMPK pathway, it restores normal fat handling in these cells. If this works in clinical studies, GLP-1 drugs could become a treatment for dry AMD.

What causes AMD?

AMD is caused by the accumulation of lipid-rich deposits (drusen) under the retina, oxidative stress, and progressive dysfunction of retinal pigment epithelium cells. These are the exact problems liraglutide addressed in this cell study—suggesting GLP-1 drugs target AMD's core pathology, not just its symptoms.

Read the original research

Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells.

International journal of molecular sciences, 26(8)

View on PubMed ↗Publisher’s paper ↗

Citation

Tsou, Sing-Hua; Luo, Kai-Shin; Huang, Chien-Ning; Kornelius, Edy; Cheng, I-Ting; Hung, Hui-Chih; Hung, Yu-Chien; Lin, Chih-Li; Hsu, Min-Yen. (2025). Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells.. International journal of molecular sciences, 26(8). https://doi.org/10.3390/ijms26083704